Evidence map›Paper›PMID 41897302›Full record

ReviewBiomolecules2026

Navigating Challenges in Mass Spectrometry Analysis of Endogenous and Synthetic Protein Modifications.

Caroline M Hanson, Dina L Bai, Jarrod A Marto

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Caroline M HansonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Dina L BaiDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.ORCID 0000-0001-9595-1199
Jarrod A MartoDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.

Funding

Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapyR01CA279391 · NCI · DANA-FARBER CANCER INST · PI Derin B Keskin · 2024 to 2026
$2.2M
New Chemical Tools for Covalent Drug DiscoveryR61CA278449 · NCI · UNIVERSITY OF VIRGINIA · PI Justin Kim, Jarrod A. Marto · 2024 to 2026
$661k
NCI NIH HHS R01 CA279391NCI NIH HHS R61 CA278449
6 · The paper itself

Abstract

Mass spectrometry-based analysis of post-translational modifications (PTMs) is a key strategy for characterizing protein regulation and identifying disease-associated targets, with endogenous PTMs serving as biomarkers for disease diagnosis and therapeutic response. More recently, chemical proteomic strategies have adapted PTM-focused workflows to measure engagement of covalent and photoactivatable small-molecule probes, expanding the scope of ligand discovery for these disease-associated targets. This review provides an overview of mass spectrometry-based PTM analysis workflows, including LC-MS/MS acquisition and post-acquisition data processing, with an emphasis on how modification-specific physicochemical properties influence PTM detection and identification. Common analytical challenges that limit PTM identification, including variable MS/MS fragmentation behavior and modification site localization, are discussed using modifications such as phosphorylation and photoaffinity labeling probe adducts as representative examples. Recent advances in acquisition strategies and computational tools that improve spectral quality and confidence in PTM assignment are also summarized. Additionally, approaches for the analytical validation of modification events, such as metabolic labeling strategies, are described. Together, this review outlines key considerations, capabilities, and limitations of MS-based PTM profiling and provides a framework for interpreting PTM datasets to support their effective integration into downstream biochemical and disease target validation studies.

Indexed as

Mass SpectrometryProtein Processing, Post-TranslationalProteinsProteomicsAnimalsHumansTandem Mass SpectrometryProteinschimeric spectracollision induced dissociation (CID)database searchdiagnostic iondynamic exclusionelectron capture dissociation (ECD)electron transfer dissociation (ETD)error-tolerant searchfragment remnantimmonium ionisobariclabeling profileopen searchparallel reaction monitoring (PRM)peptide-spectrum match (PSM)positional isomerprecursor ion scanningsite-determining ionsynthetic modification

Identifiers

PMID41897302
PMCPMC13024198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.